## TECHNE CORP /MN/

## Form 10-Q

May 09, 2008
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR $15(\mathrm{~d})$ OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2008, or
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR $15(\mathrm{~d})$ OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from $\qquad$ to $\qquad$

Commission file number 0-17272

TECHNE CORPORATION
(Exact name of registrant as specified in its charter)

MINNESOTA
(State or other jurisdiction of incorporation or organization)

```
\[
\begin{gathered}
41-1427402 \\
\text { (I.R.S. Employer }
\end{gathered}
\]
Identification No.)
614 MCKINLEY PLACE N.E.
(612) 379-8854
MINNEAPOLIS, MN 55413
(Address of principal (Zip Code)
executive offices)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or \(15(\mathrm{~d})\) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No ( )
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule \(12 \mathrm{~b}-2\) of the Exchange Act.
Large accelerated filer (X) Accelerated filer ( ) Non-accelerated filer ( ) Smaller reporting company ( )
Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2). ( ) Yes (X) No
At May 5, 2008, 38,641,599 shares of the Company's Common Stock (par value \(\$ .01)\) were outstanding.
```

MARCH 31, 2008

## Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

INDEX

PAGE NO.
PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (unaudited)

```
Condensed Consolidated Balance Sheets as of March 31, 2008 and June 30, 2007
3
```

Condensed Consolidated Statements of Earnings for the Quarter and Nine Months Ended March 31, 2008 and 2007

Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2008 and 2007

Notes to Condensed Consolidated Financial Statements

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS10
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK ..... 17
ITEM 4. CONTROLS AND PROCEDURES ..... 18
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS ..... 19
ITEN 1A. RISK FACTORS ..... 19
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ..... 19
ITEM 3. DEFAULTS UPON SENIOR SECURITIES ..... 19
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SHAREHOLDERS ..... 19
ITEM 5. OTHER INFORMATION ..... 19
ITEM 6. EXHIBITS ..... 19
SIGNATURES ..... 20

2

PART I. FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)
3/31/08 6/30/07

ASSETS
Cash and cash equivalents
$\$ 162,849 \$ 135,485$
Short-term available-for-sale investments
42,947 29,289

| Trade accounts receivable, net | 32,798 | 29,559 |
| :---: | :---: | :---: |
| Other receivables | 1,407 | 1,407 |
| Inventories | 10,003 | 8,757 |
| Deferred income taxes | 8,236 | 7,446 |
| Prepaid expenses | 1,121 | 895 |
| Total current assets | 259,361 | 212,838 |
| Available-for-sale investments | 75,097 | 91,433 |
| Property and equipment, net | 94,069 | 91,535 |
| Goodwill | 25,068 | 25,068 |
| Intangible assets, net | 4,246 | 5,099 |
| Deferred income taxes | 4,366 | 4,362 |
| Investments in unconsolidated entities | 25,052 | 24,165 |
| Other assets | 851 | 344 |
|  | \$488,110 | \$454, 844 |
| IABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| Trade accounts payable | \$ 4,852 | \$ 5,098 |
| Salaries, wages and related accruals | 5,977 | 6,013 |
| Other accounts payable and accrued expenses | 3,077 | 1,836 |
| Income taxes payable | 6,256 | 4,246 |
| Total current liabilities | 20,162 | 17,193 |
| ```Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 38,772,452 and 39,455,677, respectively``` | 388 | 395 |
| Additional paid-in capital | 114,781 | 109,993 |
| Retained earnings | 341,362 | 314,339 |
| Accumulated other comprehensive income | 11,417 | 12,924 |
| Total stockholders' equity | 467,948 | 437,651 |
|  | \$488,110 | \$454, 844 | See notes to condensed consolidated financial statements.

## 3

TECHNE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands, except per share data)
(unaudited)

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Net sales | \$69,522 | \$60,197 | \$189,651 | \$165,057 |
| Cost of sales | 14,146 | 12,019 | 39,001 | 33,970 |
| Gross margin | 55,376 | 48,178 | 150,650 | 131,087 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 8,994 | 7,229 | 27,729 | 23,126 |

Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

| Research and development <br> Amortization of intangible assets | $\begin{array}{r} 5,839 \\ 283 \end{array}$ | $\begin{array}{r} 5,169 \\ 403 \end{array}$ | $\begin{array}{r} 16,582 \\ 853 \end{array}$ | $\begin{array}{r} 15,068 \\ 1,210 \end{array}$ |
| :---: | :---: | :---: | :---: | :---: |
| Total operating expenses | 15,116 | 12,801 | 45,164 | 39,404 |
| Operating income | 40,260 | 35,377 | 105,486 | 91,683 |
| Other expense (income) : |  |  |  |  |
| Interest expense | -- | -- | -- | 1,083 |
| Interest income | $(3,155)$ | $(2,237)$ | $(9,405)$ | $(5,869)$ |
| Other non-operating expense, net | 423 | 767 | 1,565 | 1,680 |
| Total other income | $(2,732)$ | $(1,470)$ | $(7,840)$ | $(3,106)$ |
| Earnings before income taxes | 42,992 | 36,847 | 113,326 | 94,789 |
| Income taxes | 13,402 | 12,954 | 37,025 | 32,602 |
| Net earnings | \$29,590 | \$23,893 | \$ 76,301 | \$ 62,187 |
| Earnings per share: |  |  |  |  |
| Basic | \$ 0.76 | \$ 0.61 | \$ 1.94 | \$ 1.58 |
| Diluted | \$ 0.76 | \$ 0.60 | \$ 1.94 | \$ 1.57 |
| Weighted average common shares outstanding: |  |  |  |  |
| Basic | 39,000 | 39,414 | 39,296 | 39,393 |
| Diluted | 39,108 | 39,543 | 39,396 | 39,498 |

See notes to condensed consolidated financial statements.

$$
4
$$

TECHNE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)
(unaudited)

|  | NINE MOI | $S$ ENDED |
| :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| Net earnings | \$ 76,301 | \$ 62,187 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 5,254 | 5,152 |
| Deferred income taxes | (795) | (328) |
| Stock-based compensation expense | 1,663 | 1,467 |
| Excess tax benefit from stock option exercises | (409) | (329) |
| Losses by equity method investees | 836 | 634 |
| Other | 224 | 126 |
| Change in operating assets and operating liabilities: |  |  |
| Trade accounts and other receivables | $(2,557)$ | $(5,110)$ |
| Inventories | $(1,565)$ | (645) |
| Prepaid expenses | (220) | (226) |
| Trade, other accounts payable and accrued expenses | (580) | 321 |
| Salaries, wages and related accruals | 1,427 | 506 |
| Income taxes payable | 2,491 | (581) |
| Net cash provided by operating activities | 82,070 | 63,174 |


| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| :---: | :---: | :---: |
| Additions to property and equipment | $(6,914)$ | $(4,293)$ |
| Purchase of available-for-sale investments | $(42,880)$ | $(34,195)$ |
| Proceeds from sales of available-for-sale investments | 25,055 | 4,244 |
| Proceeds from maturities of available-for-sale investments | 18,898 | 13,485 |
| Increase in other assets | (608) | -- |
| Increase in investments in unconsolidated entities | $(1,723)$ | (7,900) |
| Net cash used in investing activities | $(8,172)$ | $(28,659)$ |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| Issuance of common stock | 2,630 | 1,639 |
| Excess tax benefit from stock option exercises | 409 | 329 |
| Purchase of common stock for stock bonus plans | $(1,494)$ | (1, 222 ) |
| Repurchase and retirement of common stock | $(47,807)$ |  |
| Payments on long-term debt | -- | $(13,427)$ |
| Net cash used in financing activities | $(46,262)$ | $(12,681)$ |
| Effect of exchange rate changes on cash | (272) | 4,808 |
| Net increase in cash and cash equivalents | 27,364 | 26,642 |
| Cash and cash equivalents at beginning of period | 135,485 | 89,634 |
| Cash and cash equivalents at end of period | \$162,849 | \$116,276 |
|  | ======== | $=$ |

See notes to condensed consolidated financial statements.

5

TECHNE CORPORATION \& SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

## A. BASIS OF PRESENTATION:

The unaudited condensed consolidated financial statements of Techne Corporation and Subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2007. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2007 included in the Company's Annual Report to Shareholders for fiscal 2007.

Certain consolidated balance sheet captions appearing in this interim report are as follows (in thousands):

|  | 3/31/08 | 6/30/07 |
| :---: | :---: | :---: |
| TRADE ACCOUNTS RECEIVABLE |  |  |
| Trade accounts receivable | \$ 33,067 | \$ 29,700 |
| Less allowance for doubtful accounts | 269 | 141 |
| NET TRADE ACCOUNTS RECEIVABLE | \$ 32,798 | \$ 29,559 |
| INVENTORIES |  |  |
| Raw materials | \$ 3,834 | \$ 3,821 |
| Supplies | 119 | 125 |
| Finished goods | 6,050 | 4,811 |
| TOTAL INVENTORIES | \$ 10,003 | \$ 8,757 |
| PROPERTY AND EQUIPMENT |  |  |
| Land | \$ 4,214 | \$ 4,214 |
| Buildings and improvements | 108,435 | 100,617 |
| Building construction in progress | -- | 3,205 |
| Laboratory equipment | 22,597 | 20,657 |
| Office equipment | 4,726 | 4,407 |
| Leasehold improvements | 951 | 975 |
|  | 140,923 | 134,075 |
| Less accumulated depreciation and amortization | 46,854 | 42,540 |
| NET PROPERTY AND EQUIPMENT | \$ 94,069 | \$ 91,535 |

6

|  | 3/31/08 | 6/30/07 |
| :---: | :---: | :---: |
| INTANGIBLE ASSETS |  |  |
| Customer relationships | \$ 20,200 | \$ 20,200 |
| Technology | 4,213 | 4,213 |
| Trade names and trademarks | 1,396 | 1,396 |
|  | 25,809 | 25,809 |
| Less accumulated amortization | 21,563 | 20,710 |
| NET INTANGIBLE ASSETS | \$ 4,246 | \$ 5,099 |
| ACCUMULATED OTHER COMPREHENSIVE INCOME: |  |  |
| Foreign currency translation adjustments | \$ 13,271 | \$ 13,400 |
| Unrealized losses on available-for-sale investments | $(1,854)$ | (476) |
| TOTAL ACCUMULATED OTHER COMPREHENSIVE INCOME | \$ 11, 417 | \$ 12,924 |

## B. INVESTMENTS IN AUCTION-RATE SECURITIES:

At June 30, 2007 and March 31, 2008, the Company held $\$ 18.7$ million and $\$ 22.1$ million par value, respectively, of investments in auction-rate securities, all of which are rated $A$ or above and which consist of specifically identifiable tax-free municipal revenue bonds where the underlying credit can
be specifically evaluated and rated. The Company classifies its auction-rate securities as long-term available-for-sale investments.

In mid-February 2008, market auctions, including several in the Company's auction-rate portfolio, began to fail due to insufficient buyers. The Company has determined that several of its investments in auction-rate securities are temporarily impaired and has reduced the value of its auctionrate investments to $\$ 19.6$ million as of March 31, 2008. The $\$ 2.5$ million reduction in value is reflected in accumulated other comprehensive income, a component of shareholders' equity. The Company continues to believe that it will ultimately recover all amounts invested in these securities. At April 30, 2008, the Company held $\$ 9.1$ million of these securities, which are carried at $\$ 6.6$ million.

## C. EARNINGS PER SHARE:

Shares used in the earnings per share computations are as follows (in thousands) :

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Weighted average common shares outstanding-basic | 39,000 | 39,414 | 39,296 | 39,393 |
| Dilutive effect of stock options and warrants | 108 | 129 | 100 | 105 |
| Weighted average common shares outstanding-diluted | 39,108 | 39,543 | 39,396 | 39,498 |

The dilutive effect of stock options and warrants in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 41,000 for both the quarter and nine months ended March 31, 2008 and 7,000 for both the quarter and nine months ended March 31, 2007, respectively.

## D. SEGMENT INFORMATION:

The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R\&D Systems Europe and hematology. The biotechnology segment consists of R\&D Systems' Biotechnology Division, Fortron (through June 30, 2007 when it was merged into R\&D Systems' Biotechnology Division), BiosPacific and R\&D China, which develop, manufacture and sell biotechnology research and diagnostic products worldwide. R\&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale world-wide.

Following is financial information relating to the Company's operating segments (in thousands):

QUARTER ENDED NINE MONTHS ENDED

|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| :---: | :---: | :---: | :---: | :---: |
| External sales |  |  |  |  |
| Biotechnology | \$45,090 | \$39,130 | \$123,114 | \$108,478 |
| R\&D Systems Europe | 20,226 | 17,403 | 54,702 | 45,587 |
| Hematology | 4,206 | 3,664 | 11,835 | 10,992 |
| Total consolidated net sales | \$69,522 | \$60,197 | \$189,651 | \$165,057 |
|  | ======= | ======= | $=======$ | = = = = = = = |
| Earnings before income taxes |  |  |  |  |
| Biotechnology | \$32,246 | \$28,537 | \$ 86,687 | \$ 75,983 |
| R\&D Systems Europe | 11,160 | 8,276 | 28,788 | 20,218 |
| Hematology | 1,175 | 1,061 | 3,185 | 3,113 |
| Corporate and equity method investees | $(1,589)$ | $(1,027)$ | $(5,334)$ | $(4,525)$ |
| Total earnings before income taxes | \$42,992 | \$36,847 | \$113,326 | \$ 94,789 |
|  | ======= | ======= | ======= | ======= |

## E. STOCK OPTIONS:

Option activity under the Company's stock option plans during the nine months ended March 31, 2008 was as follows:

|  | $\begin{gathered} \text { SHARES } \\ (\mathrm{in} \mathrm{000's)} \end{gathered}$ | WEIGHTED AVG. <br> EXERCIES PRICE | WEIGHTED <br> AVG. <br> CONTRACTUAL <br> LIFE (Yrs.) | AGGREGATE <br> INTRINSIC <br> VALUE |
| :---: | :---: | :---: | :---: | :---: |
| Outstanding at June 30, 2007 | 423 | \$43.29 |  |  |
| Granted | 38 | \$65.88 |  |  |
| Exercised | (76) | \$35.10 |  |  |
| Forfeited or expired | (1) | \$36.50 |  |  |
| Outstanding at March 31, 2008 | $\begin{array}{r} 384 \\ ==== \end{array}$ | \$47.16 | 5.4 | \$7.7 million |
| Exercisable at March 31, 2008 | 339 | \$45.56 | 5.3 | \$7.4 million |

8

The fair value of options granted under the Company's stock option plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Dividend yield | -- | -- | -- |  |
| Expected annualized volatility | N/A | 47\% | 24\%-46\% | 31\%-47\% |
| Risk free interest rate | N/A | 4.8\% | 4.2\%-4.6\% | 4.7\%-5.1\% |
| Expected life | N/A | 8 years | 7 years | 7 years |
| Weighted average fair value of options granted | N/A | \$32.88 | \$35.75 | \$31.53 |

The Company has not paid cash dividends and does not have any plans to do so, therefore an expected dividend yield of zero was used to estimate fair value of options granted. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S.

Treasury constant maturity interest rate with a term consistent with the expected life of the options granted. Separate groups of employees that have similar historical exercise behavior with regard to option exercise timing and forfeiture rates are considered separately in determining option fair value.

The total intrinsic value of options exercised during the quarter and nine months ended March 31, 2008 was $\$ 37,000$ and $\$ 2.1$ million, respectively. The total intrinsic value of options exercised during the quarter and nine months ended March 31, 2007 was $\$ 715,000$ and $\$ 969,000$, respectively. Stock option exercises are satisfied through the issuance of new shares. The total fair value of options vested during the quarter and nine months ended March 31, 2008 was $\$ 164,000$ and $\$ 1.7$ million, respectively. The total fair value of options vested during the quarter and nine months ended March 31, 2007 was $\$ 164,000$ and $\$ 1.5$ million, respectively.

Stock-based compensation cost of $\$ 77,000$ and $\$ 1.7$ million was included in selling, general and administrative expense for the quarter and nine months ended March 31, 2008, respectively. Stock-based compensation cost of $\$ 238,000$ and $\$ 1.5$ million was included in selling, general and administrative expense for the quarter and nine months ended March 31, 2007 , respectively. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. As of March 31, 2008, there was $\$ 500,000$ of total unrecognized compensation cost related to nonvested stock options that will be expensed over fiscal years 2008 through 2010.

## F. COMPREHENSIVE INCOME:

Comprehensive income and the components of other comprehensive income were as follows (in thousands):

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Net earnings | \$29,590 | \$23,893 | \$ 76,301 | \$ 62,187 |
| ```Other comprehensive income, net of tax: Foreign currency translation adjustments``` | $560$ | $498$ | (129) | 4,949 |
| Unrealized gain (loss) on available-for-sale investments | (2,039) | 22 | $(1,378)$ | 543 |
| Comprehensive income | \$28,111 | \$24,413 | \$ 74,794 | \$ 67,679 |

9

## G. INCOME TAXES:

The Company adopted Financial Accounting Standards Board Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes, on July 1, 2007. The adoption of FIN 48 did not result in a cumulative effect adjustment to retained earnings upon adoption. FIN 48 did not materially impact the consolidated financials statements for the quarter and nine months ended March 31, 2008. At March 31, 2008, unrecognized tax benefits were $\$ 81,000$, including $\$ 6,000$ of unrecognized tax benefits that, if recognized, would affect the effective tax rate. Accrued interest and penalties were not material at March 31, 2008.

## Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. The Company files income tax returns in the U.S federal tax jurisdiction, the states of Minnesota, California and Massachusetts, and several jurisdictions outside the U.S. U.S. tax returns for 2005 and subsequent years remain open to examination by the tax authorities. The Company's major non-U.S. tax jurisdictions are the United Kingdom, France and Germany, which have tax years open to exam for 2004 and subsequent years, and China, which has calendar year 2007 open to exam.

## H. STOCK REPURCHASE:

In November 2007, the Board of Directors of the Company authorized the repurchase and retirement of $\$ 150$ million of common stock. During the nine months ended March 31, 2008, the Company repurchased and retired approximately 758,000 shares of common stock for approximately $\$ 49.3$ million. Included in other accounts payable at March 31, 2008 is $\$ 1.5$ million for shares repurchased prior to March 31, 2008 which settled after that date.

## I. SUBSEQUENT EVENT:

On April 17, 2008, the Company purchased the facility it had been leasing for its R\&D Europe operations in Abingdon, England for approximately 4.1 million British pounds (approximately $\$ 8.2$ million).

## ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations for the Quarter and Nine Months Ended March 31, 2008 and the Quarter and Nine Months Ended March 31, 2007

## Overview

TECHNE Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted domestically through its wholly-owned subsidiary, Research and Diagnostic Systems, Inc (R\&D Systems). The Company's wholly-owned U.K. subsidiary, R\&D Systems Europe Ltd. (R\&D Europe) distributes R\&D Systems' biotechnology products throughout Europe. R\&D Europe has a sales subsidiary, R\&D Systems GmbH, in Germany and a sales office in France.

Through June 30, 2007, R\&D Systems operated a subsidiary, Fortron Bio Science, Inc. (Fortron), a developer and manufacturer of monoclonal and polyclonal antibodies, antigens and other biological reagents. Subsequent to June 30, 2007, Fortron was merged into R\&D Systems. A second R\&D Systems subsidiary, BiosPacific, Inc. (BiosPacific), located in Emeryville, California, is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. In late fiscal 2007, R\&D Systems established a subsidiary, R\&D Systems China Co. Ltd. (R\&D China), in Shanghai, China, to distribute biotechnology products throughout China. The

# Edgar Filing: TECHNE CORP /MN/ - Form 10-Q 

Company began fulfilling orders for its third-party Chinese distributors from R\&D China in August 2007.

The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R\&D Systems Europe and hematology. The biotechnology segment consists of R\&D Systems' Biotechnology Division, Fortron (through June 30, 2007), BiosPacific and R\&D China, which develop, manufacture and sell biotechnology research and diagnostic products world-wide. R\&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale world-wide.

Overall Results

Consolidated net earnings increased $23.8 \%$ and $22.7 \%$ for the quarter and nine months ended March 31, 2008, respectively, compared to the quarter and nine months ended March 31, 2007. The primary reason for the increase in consolidated net earnings was increased consolidated net sales. Consolidated net sales for the quarter and nine months ended March 31, 2008, increased 15.5\% and 14.9\%, respectively, from the same periods in the prior year. Consolidated net sales were favorably affected by the strength of foreign currencies as compared to the U.S. dollar. The favorable impact on consolidated net sales of the change from the prior year in exchange rates used to convert sales in foreign currencies into U.S. dollars was \$1.8 million and $\$ 4.2$ million for the quarter and nine months ended March 31, 2008, respectively. The favorable impact on consolidated net earnings of the change from the prior year in exchange rates used to convert foreign currencies (primarily British pound sterling and Euros) to U.S. dollars was $\$ 251,000$ and $\$ 1.0$ million for the quarter and nine months ended March 31, 2008, respectively. The Company generated cash of $\$ 82.1$ million from operating activities in the first nine months of fiscal 2008, paid cash of $\$ 47.8$ million for the repurchase of common stock in the first nine months of fiscal 2008 and had cash, cash equivalents and available-for-sale investments of $\$ 281$ million at March 31, 2008 compared to $\$ 256$ million at June 30, 2007 .

Net Sales

Consolidated net sales for the quarter and nine months ended March 31, 2008 were $\$ 69.5$ million and $\$ 189.7$ million, respectively, increases of $\$ 9.3$ million (15.5\%) and $\$ 24.6$ million (14.9\%) from the quarter and nine months ended March 31, 2007. Biotechnology net sales increased $\$ 6.0$ million (15.2\%) and $\$ 14.6$ million (13.5\%), respectively, for the quarter and nine months ended March 31, 2008. Approximately $\$ 1.1$ million and $\$ 1.8$ million of the increase in biotechnology net sales for the quarter and nine months ended March 31, 2008 was a result of increased volume and timing of shipments to diagnostic customers. The timing of shipments to diagnostic customers is not predictable and these sales increases are not necessarily indicative of future sales. Excluding sales to diagnostic customers, biotechnology net sales increased $13.2 \%$ and $12.6 \%$ for the quarter and nine months ended March 31, 2008, respectively.

R\&D Europe net sales increased $\$ 2.8$ million (16.2\%) and $\$ 9.1$ million (20.0\%) for the quarter and nine months ended March 31, 2008. R\&D Europe's net sales increased $6.0 \%$ and $10.9 \%$ for the quarter and nine months ended March 31, 2008, respectively, when measured at currency rates in effect in the comparable prior periods, mainly as a result of increased sales volume.

Hematology sales increased $\$ 542,000$ (14.8\%) and $\$ 843,000$ (7.7\%) for the quarter and nine months ended March 31, 2008. The timing of shipments to OEM
customers positively impacted Hematology sales results during the quarter ended March 31, 2008.

The Company has target annual sales growth rates for each of its business segments. The target sales growth rates, which are based on historical sales growth, are $10 \%-12 \%$ for biotechnology, $7 \%-9 \%$ for $R \& D$ Europe (in constant currency) and $1 \%-2 \%$ for hematology. Based on the relative size of each segment and current market conditions, the consolidated targeted annual growth rate is $8 \%-10 \%$, excluding the effect of changes in exchange rates.

Gross Margins

Gross margins, as a percentage of net sales, were as follows:

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Biotechnology | $79.8 \%$ | $80.4 \%$ | $79.8 \%$ | 80.3\% |
| R\&D Europe | $56.9 \%$ | $53.8 \%$ | 56.1 \% | $52.8 \%$ |
| Hematology | 41.4\% | 43.1 \% | $40.8 \%$ | $42.4 \%$ |
| Consolidated gross margin | $79.7 \%$ | $80.0 \%$ | $79.4 \%$ | $79.4 \%$ |

Consolidated gross margins, as a percentage of net sales, decreased slightly from $80.0 \%$ for the quarter ended March 31, 2007 to $79.7 \%$ for the quarter ended March 31, 2008. The decrease for the quarter was mainly the result of increased sales to diagnostic customers, which reduced biotechnology gross margins from 80.4\% for the quarter ended March 31, 2007 to 79.8\% for the quarter ended March 31, 2008. This decrease was partially offset by increased gross margins by R\&D Europe for the quarter ended March 31, 2008 as a result of favorable exchange rates. Consolidated gross margins, as a percentage of net sales for the nine months ended March 31, 2008 were 79.4\%, similar to the same prior-year period, with lower biotechnology margins offset by increased gross margins by R\&D Europe as a result of favorable exchange rates and changes in sales mix as a result of higher sales growth in biotechnology and R\&D Europe as compared to the sales growth in the lower margin hematology business.

The Company values its manufactured protein and antibody inventory based on a two-year forecast. Quantities in excess of the two-year forecast are considered impaired and are not included in the inventory value. Sales of previously impaired protein and antibody inventory for the quarter and nine months ended March 31, 2008 and 2007 were not material.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the quarter and nine months ended March 31, 2008, increased $\$ 1.8$ million (24.4\%) and $\$ 4.6$ million (19.9\%), respectively, from the same periods of last year. Selling, general and administrative expenses are composed of the following (in thousands):

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Biotechnology | \$ 5, 257 | \$ 4,166 | \$ 15,415 | \$ 12,843 |
| R\&D Europe | 2,311 | 2,112 | 7,172 | 6,537 |
| Hematology | 489 | 431 | 1,443 | 1,268 |
| Corporate | 937 | 520 | 3,699 | 2,478 |
| Total selling, general and administrative expenses | \$ 8,994 | \$ 7,229 | \$ 27,729 | \$ 23,126 |

The increase from the comparable prior-year periods was primarily the result of the following (in thousands):

|  | QUARTER <br> INCREASE <br> (DECREASE) | NINE MONTHS <br> INCREASE |
| :---: | :---: | :---: |
| Biotechnology: |  |  |
| Profit sharing expense | \$ 550 | \$ 1,031 |
| China selling, general and administrative expense | 149 | 392 |
| Bad debt expense | 124 | 124 |
| R\&D Europe: |  |  |
| Change in exchange rates to convert British pounds to U.S dollars | 27 | 310 |
| Hematology: |  |  |
| Profit sharing expense | 70 | 125 |
| Corporate: |  |  |
| Legal fees | 559 | 930 |
| Stock-based compensation expense | (161) | 196 |

The increase in profit sharing expense for the quarter and nine months ended March 31,2008 was the result of the increased sales and earnings from the same prior-year periods. Operations in China were established in late fiscal 2007, resulting in increased expenses in fiscal 2008. The increase in legal fees for the quarter and nine months ended March 31, 2008 was due to on-going patent interference and infringement litigation. The increase in stock-based compensation expense for the nine months ended March 31, 2008, was due to an increase in the number of stock options granted in fiscal 2008 compared to fiscal 2007 as a result of expanding the Board of Directors by one member. The remainder of the increase in selling, general and administrative expenses for the quarter and nine months ended March 31, 2008, was mainly the result of annual wage and salary increases and the hiring of additional marketing and administrative personnel.

Research and Development Expenses

Research and development expenses are composed of the following (in thousands) :

|  | QUARTER ENDED |  | NINE MONTHS ENDED |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 | 3/31/07 | 3/31/08 | 3/31/07 |
| Biotechnology | \$ 5,640 | \$ 4,971 | \$ 16,010 | \$ 14,500 |
| Hematology | 199 | 198 | 572 | 568 |
| Total research and development expenses | \$ 5,839 | \$ 5,169 | \$ 16,582 | \$ 15,068 |

## Interest Expense

On October 31, 2006, the Company repaid its mortgage debt. Included in interest expense for the nine months ended March 31, 2007 was a prepayment penalty of $\$ 651,000$ and $\$ 78,000$ of unamortized loan origination fees.

Other Non-operating Expense and Income

Other non-operating expense and income consists mainly of foreign currency transaction gains and losses, rental income, building expenses related to rental property, and the Company's share of losses by equity method investees.

|  | QUARTER ENDED |  |  |  | NINE MONTHS ENDED |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 3/31/08 |  | 3/31/07 |  | 3/31/08 |  | 3/31/07 |  |
| Foreign currency (gains) losses | \$ | (462) | \$ | 42 | \$ | (779) | \$ | 63 |
| Rental income |  | (91) |  | (55) |  | (269) |  | (595) |
| Real estate taxes, depreciation and utilities |  | 633 |  | 519 |  | 1,777 |  | 1,578 |
| Losses by equity method investees |  | 343 |  | 261 |  | 836 |  | 634 |
| Total other non-operating expense | \$ | 423 | \$ | 767 | \$ | 1,565 | \$ | 1,680 |

In February 2008, the Company invested an additional $\$ 300,000$ in Hemerus Medical, LLC (Hemerus). The Company currently holds a $19 \%$ equity interest in Hemerus and at March 31, 2008, the Company's net investment was $\$ 3.0$ million. The Company accounts for its investment in Hemerus using the equity method of accounting because Hemerus is a limited liability company. The Company has financial exposure to the losses of Hemerus to the extent of its net investment in that entity. Hemerus' success is dependent, in part, upon its ability to raise financing and receiving Federal Drug Administration (FDA) clearance to market its products. If such financing or FDA clearance is not received, the Company would potentially recognize an impairment loss to the extent of its remaining net investment.

In fiscal 2007, the Company invested $\$ 7.2$ million for an $18 \%$ equity interest in Nephromics, LLC (Nephromics). The Company accounts for its investment in Nephromics using the equity method of accounting because Nephromics is a limited liability company. At March 31, 2008, the Company's net investment in Nephromics was $\$ 6.4$ million. The Company has financial exposure to any losses of Nephromics to the extent of its net investment in that entity.

In December 2007, the Company invested $\$ 1.4$ million for a $19 \%$ interest in ACTGen, Inc., a development stage biotechnology company located in Japan. The Company has financial exposure to any losses of ACTGen, Inc. to the extent of its investment in that entity.

Income Taxes

Income taxes for the quarter and nine months ended March 31, 2008 were provided at rates of $31.2 \%$ and $32.7 \%$, respectively, of consolidated earnings before income taxes compared to $35.2 \%$ and $34.4 \%$ for the quarter and nine months ended March 31, 2007, respectively. The income tax rates for the quarter and nine months ended March 31, 2008 decreased from the comparable prior-year periods primarily as a result of changes in state apportionment estimates. U.S. federal taxes have been reduced by the credit for research and development expenditures through December 2007 , the benefit for extraterritorial income through December 2006 and the manufacturer's deduction available under the American Jobs Creation Act of 2004 . Foreign income taxes have been provided at rates that approximate the tax rates in the countries in which R\&D Europe and R\&D China operate. Without significant business developments, the company expects income tax rates for the remainder of fiscal 2008 to range from approximately $33.0 \%$ to $34.0 \%$.

## Liquidity and Capital Resources

At March 31, 2008, cash and cash equivalents and available-for-sale investments were $\$ 281$ million compared to $\$ 256$ million at June 30,2007 . The Company believes it can meet its future cash, working capital and capital addition requirements through currently available funds, cash generated from operations and maturities of available-for-sale investments. The Company has an unsecured line of credit of $\$ 750,000$. The interest rate on the line of credit is at prime. There were no borrowings on the line in the prior or current fiscal year.

Cash Flows From Operating Activities
The Company generated cash of $\$ 82.1$ million from operating activities in the first nine months of fiscal 2008 compared to $\$ 63.2$ million in the first nine months of fiscal 2007. The increase from the prior year was primarily due to an increase in consolidated net earnings in the current year of $\$ 14.1$ million and the changes in trade and other receivables and consolidated income taxes payable during the nine months ended March 31, 2008 compared to the same prior-year period. The increase in trade accounts and other receivables during the nine months ended March 31, 2008 of $\$ 2.5$ million was less than the increase of $\$ 5.1$ million for the comparable prior-year period as a result of the timing of accounts receivable collections. Income taxes payable increased during the nine months ended March 31, 2008 mainly as a result of increased income taxes currently payable of $\$ 5.2$ million partially offset by increased tax deposits of $\$ 1.9$ million from the same prior-year period.

## Cash Flows From Investing Activities

Capital expenditures for fixed assets for the first nine months of fiscal 2008 and 2007 were $\$ 6.9$ million and $\$ 4.3$ million, respectively. Included in capital expenditures for the first nine months of fiscal 2008 and 2007 were $\$ 4.6$ million and $\$ 2.6$ million, respectively, for building renovation and construction. The remaining capital additions in the first nine months of fiscal 2008 and 2007 were for laboratory and computer equipment. Capital expenditures in the remainder of fiscal 2008 are expected to be approximately $\$ 8.7$ million, including approximately $\$ 8.2$ million for the purchase of $R \& D$ Europe's facility in the U.K. Capital expenditures for the remainder of fiscal 2008 are expected to be financed through currently available funds and cash generated from operating activities.

During the nine months ended March 31, 2008, the Company purchased \$42.9 million and had sales or maturities of $\$ 43.9$ million of available-for-sale investments. During the nine months ended March 31, 2007, the Company purchased $\$ 34.2$ million and had sales or maturities of $\$ 17.7$ million of available-for-sale investment. The Company's investment policy is to place excess cash in bonds and other investments with maturities of less than three years. The objective of this policy is to obtain the highest possible return with minimal risk, while keeping the funds accessible.

During the nine months ended March 31, 2008, the Company invested $\$ 300,000$ in Hemerus and $\$ 1.4$ million for a $19 \%$ interest in ACTGen, Inc., a development stage biotechnology company located in Japan. During the nine months ended March 31, 2007, the Company invested $\$ 700,000$ in Hemerus and $\$ 7.2$ million in Nephromics. The investments were financed through cash and cash equivalents on hand.

[^0]
## Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

Cash of $\$ 2.6$ million and $\$ 1.6$ million was received during the nine months ended March 31, 2008 and 2007, respectively, from the exercise of stock options. The Company also recognized excess tax benefits from stock option exercises of $\$ 409,000$ and $\$ 329,000$ for the nine months ended March 31, 2008 and 2007, respectively.

During the first nine months of fiscal 2008 and 2007, the Company purchased 23,641 shares and 22,400 shares of common stock, respectively, for its employee stock bonus plans at a cost of $\$ 1.5$ million and $\$ 1.2$ million, respectively.

During the first nine months of fiscal 2008, the Board of Directors authorized the Company, subject to market conditions and share price, to purchase an additional $\$ 150$ million of its common stock. During the first nine months of fiscal 2008, the Company purchased and retired approximately 758,000 shares of common stock at a market value of $\$ 49.3$ million of which $\$ 47.8$ million was disbursed prior to March 31, 2008.

The Company has never paid cash dividends and has no plans to do so in fiscal 2008.

## Critical Accounting Policies

The Company's significant accounting policies are discussed in the Company's Annual Report on Form $10-\mathrm{K}$ for fiscal 2007. The application of certain of these policies require judgments and estimates that can affect the results of operations and financial position of the Company. Judgments and estimates are used for, but not limited to, accounting for the allowance for doubtful accounts, inventory valuation and allowances, impairment of goodwill, intangibles and other long-lived assets, accounting for investments and income taxes. There have been no significant changes in estimates in fiscal 2008 which would require disclosure. There have been no changes to the Company's policies in fiscal 2008.

Recent Accounting Pronouncements
In December 2007, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standard (SFAS) No. 141 (revised 2007), Business Combinations (SFAS No. 141R), which replaces SFAS No. 141. The statement retains the purchase method of accounting for acquisitions, but requires a number of changes, including changes in the way assets and liabilities are recognized in the purchase accounting. It also changes the recognition of assets acquired and liabilities assumed arising from contingencies, requires the capitalization of in-process research and development at fair value, and requires the expensing of acquisition-related costs as incurred. SFAS No. 141R must be applied prospectively to business combinations consummated by the Company beginning in fiscal 2010.

In December 2007, the FASB issued SFAS No. 160, Noncontroling Interests in Consolidated Financial Statements, an Amendment of ARB No. 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Among other requirements, SFAS No. 160 clarifies that a noncontrolling interest in a subsidiary, which is sometimes referred to as minority interest, is to be reported as a separate component of equity in the consolidated financial statements. SFAS No. 160 also requires consolidated net income to include the amounts attributable to both the parent and the noncontrolling interest and to disclose those amounts on the face of the consolidated statement of income. SFAS No. 160 must be applied prospectively by the Company beginning

## Edgar Filing: TECHNE CORP /MN/ - Form 10-Q

in fiscal 2010, except for the presentation and disclosure requirements, which will be applied retrospectively for all periods presented.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. The Statement establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS No. 157 applies only to fair value measurements that are already required or permitted by other accounting standards and is effective for the Company in fiscal 2009. In February 2008, the FASB deferred the effective date of SFAS No. 157 for one year as it relates to the fair value measurement requirements for nonfinancial assets and nonfinancial liabilities, except for items that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company is currently evaluating the impact of adopting SFAS No. 157.

Forward Looking Information and Cautionary Statements

This filing contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements include those regarding the Company's expectations as to target sales growth rates, the ability to recover amounts invested in auction-rate securities, compensation expense resulting from stock option expensing, the effective tax rate, plans not to pay cash dividends, the sufficiency of currently available funds for meeting the Company's needs and capital expenditures. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM (private label) and proficiency survey business, the impact of currency exchange rate fluctuations, the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships, and the success of financing efforts by companies in which the Company has invested. For additional information concerning such factors, see the Company's Annual Report on Form $10-\mathrm{K}$ as filed with the Securities and Exchange Commission.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At March 31, 2008, the Company had an investment portfolio of fixed income securities, excluding those classified as cash and cash equivalents, of \$118 million. These securities, like all fixed income instruments, are subject to interest rate risk and will decline in value if market interest rates increase.

At June 30, 2007 and March 31, 2008, the Company held $\$ 18.7$ million and $\$ 22.1$ million par value, respectively, of investments in auction-rate securities, all of which are rated $A$ or above and which consist of specifically identifiable tax-free municipal revenue bonds where the underlying credit can be specifically evaluated and rated. The Company classifies its auction-rate securities as long-term available-for-sale investments.

In mid-February 2008, market auctions, including several in the Company's auction-rate portfolio, began to fail due to insufficient buyers. The Company has determined that several of its investments in auction-rate securities are temporarily impaired and has reduced the value of its auction-
rate investments to $\$ 19.6$ million as of March 31, 2008. The $\$ 2.5$ million reduction in value is reflected in accumulated other comprehensive income, a component of shareholders' equity. The Company continues to believe that it will ultimately recover all amounts invested in these securities. At April 30, 2008, the Company held $\$ 9.1$ million of these securities, which are carried at $\$ 6.6$ million.

The Company operates internationally, and thus is subject to potentially adverse movements in foreign currency rate changes. The Company is exposed to market risk from foreign exchange rate fluctuations of the euro (approximately $17 \%$ of consolidated net sales), the British pound sterling (approximately $8 \%$ of consolidated net sales) and the Chinese yuan (approximately 1\% of consolidated net sales) to the U.S. dollar as the financial position and operating results of the Company's U.K. subsidiary, European operations and Chinese subsidiary are translated into U.S. dollars for consolidation. At the current level of R\&D Europe operating results, a $10 \%$ increase or decrease in the average exchange rate used to translate operating results into U.S. dollars would have an approximate $\$ 2.5$ million effect on consolidated operating income annually.

The Company's exposure to foreign exchange rate fluctuations also arises from transferring funds from the U.K. and Chinese subsidiaries to the U.S. subsidiary and from transferring funds from the German subsidiary and French sales office to the U.K. subsidiary. At March 31, 2008 and 2007, the Company had $\$ 4.0$ million and $\$ 5.0$ million, respectively, of dollar denominated intercompany debt at its U.K. subsidiary and at March 31, 2008, the Company had $\$ 542,000$ dollar denominated intercompany debt at its Chinese subsidiary. At March 31, 2008 and 2007, the U.K. subsidiary had $\$ 459,000$ and $\$ 732,000$, respectively, of dollar denominated intercompany debt from its European operations. These intercompany balances are revolving in nature and are not deemed to be long-term balances.

The Company's subsidiaries recognized net foreign currency gains and (losses) as follows (in thousands):


The Company does not enter into foreign exchange forward contracts to reduce its exposure to foreign currency rate changes on intercompany foreign currency denominated balance sheet positions.

ITEM 4 - CONTROLS AND PROCEDURES
As of the end of the period covered by this report, the Company conducted an
evaluation, under the supervision and with the participation of the principal executive officer and principal financial officer, of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d15 (e) under the Securities Exchange Act of 1934 (the "Exchange Act")). Based on this evaluation, the principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. There was no change in the Company's internal control over financial reporting during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

None.

ITEM 1A. - RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2007.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table sets forth the repurchases of Company common stock for the quarter ended March 31, 2008:

| Total Number of Maximum |  |
| :--- | :--- |
| Shares Purchased Approximate Dollar |  |
| As Part of | Value of Shares |
| Publicly | that May Yet Be |
| d Announced Plans | Purchased Under the |
| or Programs | Plans or Programs |
| $-------------------------------------125 ~ m i l l i o n ~$ |  |
| 169,273 | $\$ 125.4$ |
| 95,587 | $\$ 119.0$ million |
| 172,441 | $\$ 107.5$ million |

In October 2002, the Company authorized the purchase and retirement of $\$ 20$ million of its common stock of which $\$ 6.8$ million remained at October 31 , 2007. In November 2007 , the Company authorized the repurchase and retirement of an additional $\$ 150$ million of common stock. The stock repurchase authorization does not have an expiration date.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - SUBMISSION OF MATTERS TO VOTE OF SHAREHOLDERS

None.

# Edgar Filing: TECHNE CORP /MN/ - Form 10-Q 

ITEM 5 - OTHER INFORMATION

None.

ITEM 6 - EXHIBITS

See exhibit index following.

19

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TECHNE CORPORATION
(Company)

```
Date: May 9, 2008
    May 9, 2008
    /s/ Thomas E. Oland
    President, Chief Executive Officer
    /s/ Gregory J. Melsen
    Chief Financial Officer
```

EXHIBIT INDEX
TO
FORM 10-Q
TECHNE CORPORATION
Exhibit \# Description
---------- -----------------
31.1 Section 302 Certification
31.2 Section 302 Certification
32.1 Section 906 Certification
32.2 Section 906 Certification


[^0]:    Cash Flows From Financing Activities

